Introduction {#sec1}
============

Adult mesenchymal stromal cells (MSCs), defined in vitro by their potential to contribute to bone-cartilage-fat cell lineages, are currently used for cell-based bone and cartilage therapies because of their ready accessibility. However, as for other adult stem cells, it is difficult to obtain sufficient MSCs for treatment. Expansion culture is therefore necessary before transplantation; however, it tends to cause the loss of long-term viability of the MSCs and their capacity to differentiate, especially into chondrocytes ([@bib38]). Different types of bone and cartilage are formed most actively during embryonic skeletogenesis from one of three precursor cell types: paraxial mesoderm, lateral plate mesoderm, and cranial neural crest. Such embryonic cells and their osteochondrogenic progeny may be as effective as or more effective than MSCs for the regeneration of adult bone and cartilage.

The early processes of in vitro differentiation of pluripotent embryonic stem cells (ESCs) mimic those of in vivo embryogenesis ([@bib30]). Therefore, ESCs and induced pluripotent stem cells (iPSCs) (collectively designated pluripotent stem cells or PSCs) would appear to be the practical source of embryonic precursor cells in humans. In fact, in vitro induction of osteogenesis and chondrogenesis from human PSCs (hPSCs) and mouse (mPSCs) has been demonstrated by many groups ([@bib27]). With the exception of recent reports, including ours ([@bib9; @bib11; @bib28; @bib41; @bib42; @bib47]), many of the earlier reports described spontaneous differentiation of hPSCs followed by enrichment of mesenchymal cells by further culturing the progeny in MSC medium. As adult human tissue-derived MSCs or chondroprogenitors ([@bib17; @bib33]), mesenchymal cells derived from mESCs/iPSCs were able to be expanded extensively; however, expansion occurred with the loss of their chondrogenic activity ([@bib2; @bib11]). Thus far, the potential benefits of bone and cartilage repair of hPSC-derived osteochondroprogenitors over those of adult MSCs, whether in quantity or in quality, have not been demonstrated, even in vitro ([@bib27]). In theory, the wealth of information on the signaling mechanisms involved in mouse skeletogenesis should be of great help in improving the expansion culture methods. However, the unclear embryonic origins of the chondrogenic activity developed from PSCs and the undefined conditions used for expansion have hampered full use of the information and thereby hindered progress.

A large portion of craniofacial bone and cartilage arises from osteochondrogenic progeny (i.e., ectomesenchyme) from cranial neural crest ([@bib36]), generated from the junction between anterior neuroectoderm and surface ectoderm ([@bib25]). Neural crest cells have been developed from hESCs in 12--28 days of differentiation culture either through neuroepithelial intermediates induced by suppression of Nodal/Activin/transforming growth factor β (TGFβ) and bone morphogenetic protein (BMP) signaling in a defined medium ([@bib5; @bib37]) or directly by activation of WNT signaling with suppression of Nodal/Activin/TGFβ signaling ([@bib24]). Further differentiation and expansion for 2--3 weeks of such neural crest cells or earlier neural cells in a serum-containing medium generate MSC-like cells with variable chondrogenic activity, but never sufficient to reproducibly form cartilage particles that accumulate proteoglycan-rich, mature matrices uniformly (hereafter designated "full-cartilage").

Our group has focused on generating and characterizing paraxial mesodermal progeny from mPSCs/hPSCs, which are highly chondrogenic ([@bib40; @bib42; @bib47]). In the current study, we report simple, effective methods for the specification of neural crest-like progeny from hPSCs and subsequent generation and expansion of chondrogenically committed ectomesenchymal cells without loss of their chondrogenic activity over 7--8 weeks in chemically defined media (CDM). The outcomes were achieved by the control of fibroblast growth factor (FGF) signaling and Nodal/Activin/TGFβ signaling. We have also defined the cellular developmental pathway from hPSCs to such ectomesenchymal cells using the neural crest markers the low-affinity nerve growth factor receptor (CD271) ([@bib19; @bib39]), and the platelet-derived growth factor receptor α (PDGFRα) ([@bib26; @bib45]), and the MSC markers, CD73 and CD13 ([@bib32; @bib33]).

Results {#sec2}
=======

Signaling Requirement for Early Development of Neural Crest-like Progeny from hPSCs {#sec2.1}
-----------------------------------------------------------------------------------

Generation of osteochondrogenic ectomesenchyme from hPSCs first requires specification of cranial neural crest-like progeny. In order to reproducibly generate strong chondrogenic activity from hPSCs, we first optimized the method for specification of neural crest using CD271 as the readout. Fluorescence-activated cell sorting (FACS) analyses revealed that when H9 hESCs and BJ5 hiPSCs were differentiated in CDM using the conventional embryoid body (EB)-forming culture or 2D differentiation culture in the presence of SB431542 or other Nodal/Activin/TGFβ signaling inhibitor (e.g., A83-01 or SJN2511), they generated progeny that expressed CD271 ([Figures 1](#fig1){ref-type="fig"}A and [S1](#app2){ref-type="sec"}). The CD271^hi^ cell population, but not the CD271^lo/−^ progeny, also expressed PDGFRα at low levels. Both populations lacked CD73 and CD13. The effect of SB431542 was dose dependent at least up to 10 μM ([Figure S1](#app2){ref-type="sec"}D).

The CD271^hi^PDGFRα^lo^ cell development reached a peak around day 6 of differentiation ([Figure S1](#app2){ref-type="sec"}C), in parallel with the highest expression of the "neural crest specifier" genes *PAX3* and *PAX7* ([@bib29]) ([Figure 1](#fig1){ref-type="fig"}B). In contrast, the neuroectoderm marker *SOX1* was never induced, and the ESC marker *NANOG* was downregulated. Furthermore, the isolated CD271^hi^(PDGFRα^lo^)CD73^−^ progeny had higher levels of *SOX10* and *FOXD3* transcripts than the CD271^lo/−^(PDGFRα^−^)CD73^−^ cells, indicating enrichment of the fraction with neural crest-like progeny ([Figure 1](#fig1){ref-type="fig"}D). SOX9 is also implicated in the specification of cranial neural crest ([@bib29]) and is expressed in premigratory human neural crest ([@bib3]). The SOX9 reporter, GFP ([Figures 1](#fig1){ref-type="fig"}F and [S1](#app2){ref-type="sec"}I) and *SOX9* transcripts ([Figure S1](#app2){ref-type="sec"}G) were expressed in the CD271^hi^CD73^−^ fraction. The PAX3 protein ([Figure 1](#fig1){ref-type="fig"}E) and *PAX3* transcript ([Figure S1](#app2){ref-type="sec"}G) were also detected in the CD271^hi^CD73^−^ fraction.

Furthermore, in sharp contrast to the results obtained from the hPSC differentiation to paraxial mesoderm ([@bib42]), when *MIXL1* (an early mesendoderm gene)-green fluorescence protein (GFP) knockin hESCs (MIXL1-GFP) ([@bib10]) were differentiated under similar conditions, no MIXL1-GFP^+^ progeny developed ([Figure 1](#fig1){ref-type="fig"}A). There was also negligible induction of a second mesendoderm transcript, *T* ([Figure S1](#app2){ref-type="sec"}B) ([@bib42]). Therefore, neither CD271^hi^(PDGFRα^lo^)CD73^−^ nor CD271^lo^(PDGFRα^−^)CD73^−^ cells were likely to be mesendodermal derivatives.

BMP and WNT are implicated in the neural crest specification ([@bib25]). As expected, the BMP inhibitor Noggin suppressed the SB431542-induced development of the CD271^hi^PDGFRα^lo^(CD73^−^) neural crest-like progeny from H9 hESCs ([Figure S1](#app2){ref-type="sec"}E). The WNT inhibitor FZD also showed an inhibitory effect, consistent with the findings of [@bib24] ([Figure S1](#app2){ref-type="sec"}D). Interestingly, BMP4 at 10 ng/ml, a concentration sufficient to induce mesoderm ([@bib43]), was as inhibitory as Noggin, and the GSK3 inhibitor that mimics canonical WNT signaling showed weakly inhibitory effects ([Figure S1](#app2){ref-type="sec"}E). However, when SOX9-GFP iPSCs were used, the GSK3 inhibitor was found to enhance the genesis of CD271^hi^CD73^−^ cells ([Figure S1](#app2){ref-type="sec"}I).

Thus, inhibition of Nodal/Activin/TGFβ signaling with appropriate levels of BMP and WNT signaling is required for the effective development of CD271^hi^PDGFRα^lo^CD73^−^CD13^−^ neural crest-like progeny from hPSCs (hereafter called CD271^hi^CD73^−^ progeny) more quickly than previously attained ([@bib20; @bib24]), potentially reflecting the specification of cranial instead of trunk neural crest cells.

Mesenchymal Cells Derived from the Nonmesendodermal hESC Progeny by Conventional Methods Show Weak, Transient Chondrogenic Activity {#sec2.2}
-----------------------------------------------------------------------------------------------------------------------------------

The neural crest-like progeny were then directed to commit to chondrogenic ectomesenchyme. First, using a conventional EB-outgrowth method ([@bib14]) ([Figure S2](#app2){ref-type="sec"}A), we generated mesenchymal cells from the SB431542-treated H9 and MIXL1-GFP hESCs. In knockout serum replacement-based SR medium or serum-containing D10 medium, expansion of the outgrowth cells led to enhanced expression of CD73 and later CD13, but loss of the expression of CD271 ([Figures S2](#app2){ref-type="sec"}D and S2E). As we reported previously ([@bib42]), MIXL1-GFP^+^ mesendodermal progeny were never detected during such studies (data not shown).

In 3D-pellet culture, the generated mesenchymal cells gave rise to a particle containing an area that weakly stained metachromatically (pink to purple) with Toluidine Blue and immunostained with anti-type II collagen (COL2) antibody at passage 1 (p1) ([Figure S2](#app2){ref-type="sec"}F) and p2, but not from p3 to p5. The lack of chondrogenic activity in the primary outgrowth cells (p0), suggests that a short-term expansion of the outgrowth cells is required for its development and/or accumulation. However, as reported by others ([@bib27]), we did not observe robust chondrogenic activity leading to a full-cartilage particle, as found for paraxial mesoderm derived from mPSCs and hPSCs ([@bib28; @bib42]). Thus, conventional culture methods failed to generate and maintain strong chondrogenic activity from hPSC-derived neural crest-like progeny.

Generation and Selective Expansion of CD271^+^PDGFRα^+^CD73^+^ Mesenchymal Cells in CDM in the Presence of FGF2 and SB431542 {#sec2.3}
----------------------------------------------------------------------------------------------------------------------------

Either in a FACS-purified form or in an unpurified mixture with other nonmesendodermal (i.e., MIXL1^−^) cells, the CD271^hi^CD73^−^ neural crest-like progeny failed to adhere to the culture dish in the absence of fibronectin and grew poorly in the medium in which they were specified, i.e., CDM plus SB431542 (SB; [Figures 2](#fig2){ref-type="fig"}B and [S3](#app2){ref-type="sec"}A). Therefore, we tested the effects of growth factors, such as FGF2 that have been used for maintaining neural crest cells ([@bib39]) and generating chondrogenic activity ([@bib1]) in culture, and of other factors, such as endothelin1, PDGF, and Sonic hedgehog that have been linked to cranial skeletogenesis and ectomesenchymal specification in vivo ([@bib18]). FGF2 alone significantly increased viability and supported growth of the neural crest-like progeny on fibronectin but was often associated with significant slowdown in an early stage of expansion culture. The addition of both FGF2 and SB431542 maintained the growth rate at least until p16 and supported maintenance of the normal karyotype at least to p10 ([Figure S3](#app2){ref-type="sec"}B).

Direct expansion of the nonmesendodermal progeny mix in CDM in the presence of FGF2 and SB431542 resulted in accumulation of CD271^+^PDGFRα^+^CD73^+^ mesenchymal cells ([Figures 2](#fig2){ref-type="fig"}C, [S3](#app2){ref-type="sec"}, and [S4](#app2){ref-type="sec"}). The cells were positive for the MSC markers CD105, CD166, CD29, CD44, and CD56, but negative for MSC markers CD13 and STRO1 ([Figures S3](#app2){ref-type="sec"}D and S3E). In contrast, CD271 expression decreased in the presence of FGF2 alone, causing the CD271^−^PDGFRα^+^CD73^+^ cells to become the predominant cell population by p3 ([Figure 2](#fig2){ref-type="fig"}C). Similar results were obtained from expansion in D10 medium. The BMP receptor inhibitor LDN193189 was unable to replace SB431542. Interestingly, as with EB-outgrowth cell culture ([Figures S2](#app2){ref-type="sec"}D and S2E), CD13^+^ cells appeared later (from p6) under FGF2, but not FGF2+SB431542, conditions ([Figure S3](#app2){ref-type="sec"}D).

The expression of the neural crest genes *FOXD3* and *SOX10* was quickly downregulated during expansion under either FGF2 or FGF2+SB431542 conditions, even at p1, indicating rapid non-neural commitment of the neural crest-like progeny ([Figure 2](#fig2){ref-type="fig"}E) ([@bib29]). In contrast, the *SOX9* transcript was strongly upregulated at p1 and maintained over seven passages under FGF2+SB431542 conditions, whereas the *SOX9* transcript was slightly enhanced at p1 and gradually declined after p4 under FGF2 conditions.

Our results indicate that activation of FGF signaling and suppression of Nodal/Activin/TGFβ signaling during expansion of the unsorted nonmesendodermal progeny of hPSCs selectively lead to the accumulation of *SOX9*-expressing CD271^+^PDGFRα^+^CD73^+^CD13^−^ ectomesenchymal cells (hereafter called CD271^+^CD73^+^ cells).

The CD271^+^CD73^+^ Ectomesenchymal Cells Are Derived from the CD271^hi^CD73^−^ Neural Crest-like Progeny {#sec2.4}
---------------------------------------------------------------------------------------------------------

To determine the cellular origin of the CD271^+^CD73^+^ ectomesenchymal cells expanded under FGF2+SB431542 conditions, the CD271^hi^CD73^−^ and CD271^lo^CD73^−^ progeny, developed from H9 hESCs and BJ5 hiPSCs, were sorted by FACS ([Figures 1](#fig1){ref-type="fig"}C and [S1](#app2){ref-type="sec"}H) and then cultured in CDM in the presence of FGF2 and one of three Nodal/Activin/TGFβ inhibitors, SB431542, A83-01, or SJN2511. While FGF2 alone supported the accumulation of CD271^−^CD73^+^ cells from either progeny, the FGF2+SB431542, FGF2+A83-01, and FGF2+SJN2511 conditions preferentially supported the development of CD271^+^CD73^+^ cells from the sorted CD271^hi^CD73^−^ neural crest-like progeny ([Figures 3](#fig3){ref-type="fig"}B and [S4](#app2){ref-type="sec"}G). Concentrations of SB431542 between 1 and 3 μM were sufficient for the stable maintenance of CD271^+^CD73^+^ cells ([Figure S3](#app2){ref-type="sec"}C). On the other hand, most of the CD271^lo^CD73^−^ progeny did not survive, even under FGF2+SB431542 conditions, and the derived mesenchymal cells were a mixture of CD271^+^CD73^+^ and CD271^−^CD73^+^ cells ([Figures 3](#fig3){ref-type="fig"}B and [S4](#app2){ref-type="sec"}G) from which the CD271^+^CD73^+^ cells were later lost.

Even at the early p3 stage, *SOX9* expression was clearly observed in the (FGF2+SB431542)-cultured, but not the FGF2-cultured CD271^hi^CD73^−^ neural crest-like cells ([Figure 3](#fig3){ref-type="fig"}C). *SOX9* expression was not sustained during the growth of CD271^lo^CD73^−^ cells under either condition. The nuclear localization of SOX9 protein was also obvious in 76% (p10) to 85% (p8) of the (FGF2+SB431542)-expanded CD271^+^CD73^+^ cells, of which approximately 20% displayed strong signals ([Figure 3](#fig3){ref-type="fig"}D). In support of this finding, expansion of SOX9-GFP hiPSC-derived CD271^hi^CD73^−^ neural crest-like cells under FGF2+SB431542 for five passages demonstrated that approximately 20% of the cells remained CD271^+^GFP^+^, while the rest became CD271^+^GFP^lo^. No cells became CD271^+^GFP^−^ ([Figure 3](#fig3){ref-type="fig"}E).

Our results indicate that SOX9-positive CD271^+^CD73^+^ ectomesenchymal cells were generated and then expanded from the CD271^hi^CD73^−^ neural crest-like progeny of hPSCs in CDM in the presence of FGF2 and Nodal/Activin/TGFβ inhibitors and that changes to this growth condition led to the generation of *SOX9*-negative CD271^−^CD73^+^ mesenchymal cells.

The CD271^+^CD73^+^ Cells Maintain Measurable Chondrogenic Activity during Expansion {#sec2.5}
------------------------------------------------------------------------------------

Since the CD271^+^CD73^+^ ectomesenchymal cells maintained in FGF2+SB431542 express SOX9, we sought to demonstrate that they were chondrogenic using 2D micromass culture. Under the condition in which PDGF-BB was added to the chondrogenesis medium on day 0 and then replaced with TGFβ3 on day 6, which was supplemented with BMP4 on day 10 (hereafter designated as PDGF/TGFβ/BMP condition) ([@bib42]), CD271^+^CD73^+^ cells gave rise to acid Alcian Blue-positive cartilage nodules, the capacity of which lasted at least until p10 (i.e., 5 weeks) of expansion culture ([Figures 3](#fig3){ref-type="fig"}F and [S4](#app2){ref-type="sec"}A). In contrast, the CD271^−^CD73^+^ cells generated and maintained under FGF2 conditions showed weak chondrogenic activity as early as p3. The SB431542-cultured cells showed no chondrogenic activity and ceased to grow at p2.

Brief Treatment with TGFβ Facilitates Formation of Macroscopic Cartilage Particle Formation from the CD271^+^CD73^+^ Cells {#sec2.6}
--------------------------------------------------------------------------------------------------------------------------

The ectomesenchymal cells expanded in CDM in the presence of FGF2 or FGF2+SB431542 were subjected to 3D-pellet culture under the PDGF/TGFβ/BMP condition. The early (p2) FGF2-expanded cells formed a large cartilage particle that stained metachromatically (pink to purple) with Toluidine Blue, but then lost such chondrogenic activity by p4--p5 ([Figures 4](#fig4){ref-type="fig"}A and 4C), in keeping with the loss of the CD271^+^ cell population ([Figures 2](#fig2){ref-type="fig"}C and [S3](#app2){ref-type="sec"}D).

On the other hand, the (FGF2+SB431542)-expanded cells did not form a particle when subjected directly to pellet culture (no pellet, [Figure 4](#fig4){ref-type="fig"}B), suggesting that (FGF2+SB431542)-expanded cells are defective in the induction of mesenchymal condensation, a prerequisite for cartilage formation. Supporting this suggestion, 2D-micromass culture demonstrated that inclusion of SB431542 until the point of induction of chondrogenesis using TGFβ3 and BMP4 severely inhibited or delayed the formation of cartilage nodules ([Figures S4](#app2){ref-type="sec"}A and S4B). Thus, suppression of Nodal/Activin/TGFβ signaling allows the CD271^+^CD73^+^ cells to grow but not to initiate chondrogenesis under the action of TGFβ and BMP.

A brief treatment ("priming") with TGFβ is known to commit mouse neural crest stem cells to mesenchymal lineages ([@bib16]). Therefore, we reasoned that stimulation with TGFβ before pellet culture might be required for efficient cartilage particle formation. When the (FGF2+SB431542)-expanded cells were passaged once into CDM containing FGF2+TGFβ3 (FT), cultured for 3 to 4 days to confluence, and then subjected to 3D-pellet culture, large translucent full-cartilage particles filled with matrices that stained metachromatically with Toluidine Blue and immunostained with the COL2 antibody were generated effectively ([Figures 4](#fig4){ref-type="fig"}Bi, 4Bv, 4Bvi, [S4](#app2){ref-type="sec"}F, and S4H). The SB431542-dependent maintenance of chondrogenic activity during expansion culture was confirmed by the quantitative comparison of sulfated glycosaminoglycan (sGAG) levels in 24 days of pellet culture using ectomesenchymal cells maintained under FGF2+SB431542 (FSBp11→FT) and under FGF2 alone (Fp4) ([Figure 4](#fig4){ref-type="fig"}C).

When FGF2+TGFβ3 pretreatment was extended for a few more passages (FTp2), the cells maintained their particle-forming capability but gradually lost their chondrogenic potential, resulting in particles with a small cartilaginous area ([Figure 4](#fig4){ref-type="fig"}Bii). Pretreatment with D10 medium also induced pellet-forming activity in the (FGF2+SB431542)-expanded cells, which led to a full-cartilage particle ([Figure 4](#fig4){ref-type="fig"}Biii), but further maintenance in D10 completely suppressed chondrogenic activity ([Figure 4](#fig4){ref-type="fig"}Biv). Neither pretreatment was able to recover lost chondrogenic activity in FGF2-expanded cells ([Figures 4](#fig4){ref-type="fig"}Aiii and 4Aiv). A brief TGFβ pretreatment thus seemed to enhance the condensing capacity but not the chondrocyte-forming ability of the expanded ectomesenchymal cells. In support of this observation, the proportion of cells expressing SOX9 protein increased only slightly from 76%--83% ([Figure 3](#fig3){ref-type="fig"}D) to 97% ([Figure 4](#fig4){ref-type="fig"}E), and the transcription levels of *SOX9* ([Figure 4](#fig4){ref-type="fig"}F), *SOX5*, and *SOX6* (data not shown) were unaltered by the 4-day FGF2+TGFβ3 treatment.

In contrast, FGF2+TGFβ3 treatment (→FT, [Figure 4](#fig4){ref-type="fig"}D) led to dramatic downregulation of the expression of CD271 in 3 to 4 days and complete loss of expression during the subsequent culture for two passages (→FTp2). A similar change was observed with D10 treatment. Since the short-term (FGF2+TGFβ3)-treated cells effectively formed cartilage particles ([Figures 4](#fig4){ref-type="fig"}Bi, 4Biii, and 4Bv), the reduction/loss of CD271 expression may be an early indicator that chondrogenic activity will be lost later.

TGFβ upregulates the production of extracellular matrix proteins and cell surface molecules such as fibronectin, N-cadherin, and N-CAM (CD56), which are involved in the initiation of precartilaginous mesenchymal condensation ([@bib8]). CD56 but not N-cadherin was expressed on most of the (FGF2+SB431542)-expanded ectomesenchymal cells ([Figures 4](#fig4){ref-type="fig"}D and [S3](#app2){ref-type="sec"}E). However, treatment with FGF2+TGFβ3 or D10 resulted in the upregulation of N-cadherin. In addition, the (FGF2+SB431542)-expanded cells exposed to FGF2+TGFβ3 for two passages and the FGF2-expanded cells (Fp2) accumulated distinct N-cadherin^lo^ and N-cadherin^+^ populations. Together the results support the hypothesis that brief pretreatment with TGFβ enhances the precartilaginous condensing capacity of the ectomesenchymal cells expanded under FGF2+SB431542 conditions.

Property of the CD271^+^CD73^+^ Cells Maintained under FGF2+SB431542 for an Extended Period {#sec2.7}
-------------------------------------------------------------------------------------------

Since CD271^+^CD73^+^ ectomesenchymal cells maintained under FGF2+SB431542 for a long time might select a rare "permanent CD271^+^ chondrogenic cell" from the original neural crest cell population, late-passage (p10) cells were subjected to medium change to CDM with FGF2 alone. All cells started losing the CD271 expression in FGF2 and nearly 95% became CD271^−^CD73^+^ by passage 3 ([Figure 5](#fig5){ref-type="fig"}A). Those maintained in FGF2+SB431542 for four more passages were still CD271^+^CD73^+^, suggesting that maintenance of CD271 surface expression remained dependent on the presence of SB431542.

Furthermore, when 3D-pellet culture was performed, the (FGF2+SB431542)-expanded ectomesenchymal cells maintained their chondrogenic activity during further expansion (p11--16), as judged by the accumulation of sGAGs in the developed cartilage particles ([Figure 5](#fig5){ref-type="fig"}B), and the "full cartilage"-forming activity was preserved at least to p13 ([Figure 5](#fig5){ref-type="fig"}C). Interestingly, such chondrogenic activity was indistinguishable from that of the KDR^−^PDGFRα^+^ chondrogenic paraxial mesodermal cells (PM) we previously reported ([@bib42]). However, even two passages without SB431542 caused the p10 cells to begin showing signs of decline in their capacity to generate similar chondrocytes in quantity and quality (→Fp2, [Figures 5](#fig5){ref-type="fig"}D and 5E). These results indicate that expansion under FGF2+SB431542 conditions does not select a permanently chondrogenic CD271^+^ cell type and that continuous suppression of the endogenous Nodal/Activin/TGFβ signaling is necessary for preventing the loss of chondrogenic activity and CD271 expression for an extended period.

The Presence of SB431542 Maintains Expression of Genes Representing "Proliferative" and "Primitive" Stages of Differentiating Neural Crest {#sec2.8}
------------------------------------------------------------------------------------------------------------------------------------------

We performed genome-wide, comparative transcriptome analyses to elucidate the molecular basis of the effect of Nodal/Activin/TGFβ signaling-suppression on the maintenance of the proliferative and chondrogenic properties of the CD271^+^CD73^+^ ectomesenchymal cells. The CD271^hi^CD73^−^ neural crest-like progeny of H9 hESCs were isolated and expanded under FGF2+SB431542 conditions for six to seven passages (FSB, [Figure 6](#fig6){ref-type="fig"}). In some cases, the culture condition was shifted to the FGF2 condition from p4 (FSB→F). As a control, the CD271^hi^CD73^−^ cells were cultured from the outset under FGF2-conditions (F) for six passages.

The overall mRNA profiles of the three resultant cell populations demonstrated that (FGF2+SB431542)-expanded neural crest cells are distinct from both FGF2- and (FGF2+SB431542→FGF2)-expanded cells ([Figures 6](#fig6){ref-type="fig"}A and 6B), whereas little distinction was found between the last two. However, the possibility remained that the FGF2-cultured neural crest cells are different types of cells from (FGF2+SB431542)-expanded cells. Therefore, to investigate the effect of TGFβ suppression, further comparative analyses focused on (FGF2+SB431542)- and (FGF2+SB431542→FGF2)-cultured cells.

First, gene ontology (GO) analysis suggested that (FGF2+SB431542)-expanded cells would likely be involved in "DNA replication," "mitotic cell cycle," and "cell division" ([Figure 6](#fig6){ref-type="fig"}D), while (FGF2+SB431542→FGF2)-cultured cells seemed to have the property of differentiated cells and would likely be involved in "cell adhesion," "angiogenesis," and/or "skeletal system development." Furthermore, as for the predicted developmental potentials, (FGF2+SB431542)-expanded cells still showed relevance to "peripheral nervous system development," "melanocyte differentiation," and/or "eye development" ([Figure 6](#fig6){ref-type="fig"}D), although essential genes such as *SOX10*, *ASCL1-4*, *NEUROD1/2/4/6*, *NEUROG1-3*, *OLIG1-3*, *MITF*, and *PAX6* ([@bib29]) were either not (yet) expressed or expressed at very low levels (FPKM ≤1; data not shown). In contrast, (FGF2+SB431542→FGF2)-cultured cells seemed to be associated more with "ossification," "odontogenesis," and "embryonic vicerocranium morphogenesis." In addition, consistent with the removal of SB431542, enhancement of "TGFβ receptor signaling" was suggested.

Comparison of genes in either cell population that showed more than a 2.5-fold difference in expression level ([Figure 6](#fig6){ref-type="fig"}C; [Tables S3](#mmc4){ref-type="supplementary-material"} and [S4](#mmc5){ref-type="supplementary-material"}) supported the GO analysis in that genes preferentially expressed under FGF2+SB431542 conditions represented many, if not all, aspects of neural crest (stem) cells and primitive ectomesenchyme. Such genes included *LIN28A/B*, *TRIM71(LIN41)* and *MYCN* ([@bib12; @bib35]), *TWIST1/2*, *ALX1/3/4*, *SOX8/9* ([@bib29]), and *NES* as well as stem cell factor receptor (*KIT*). In contrast, *TGFB3* and other TGFβ-induced genes such as *DCN* and *THBS1/2* were induced when SB431542 was removed (FSB→F). Interestingly, the FGF2+SB431542 condition supported the expression of *COL2A1*, the type II collagen gene, SOX9 regulator genes such as *MAF* ([@bib13]) and *ZBTB16* ([@bib21]), and *LBH* ([@bib34]), while the FGF2+SB431542→FGF2 condition induced *COL1A1/1A2* and *RUNX1/2* expression, supporting their predicted "ossification" function. Consistent with FACS analyses, expression of *NGFR* (CD271), the cell surface marker gene for neural crest, was found to be supported under FGF2+SB431542 conditions, and *ANPEP* (CD13) was induced under FGF2+SB431542→FGF2. On the other hand, among genes commonly expressed in cells cultured under both conditions, the presence of *SOX4* and *SOX12* supports the likelihood that both are embryonic neural/mesenchymal progenitor cells ([@bib4]).

In Vivo Stability of the Cartilage Particle Developed In Vitro with the CD271^+^CD73^+^ Cells: A Comparative Analysis {#sec2.9}
---------------------------------------------------------------------------------------------------------------------

Cartilage particles generated under standard "PDGF/TGFβ/BMP" conditions ([@bib42]) with the CD271^+^CD73^+^ ectomesenchymal cells, derived either from a mixture of the 6-day differentiated H9 hESCs or from the FACS-isolated CD271^hi^CD73^−^ neural crest-like progeny ([Figures 7](#fig7){ref-type="fig"}C and 7D), were all mineralized after subcutaneous transplantation into immunocompromized mice for 8--12 weeks (black area with von Kossa staining), implying the capacity of the CD271^+^CD73^+^ cell to induce endochondral ossification. Consistently, the detection of *RUNX2* transcript (2D-micromass culture, [Figure 7](#fig7){ref-type="fig"}E) and *COL10A1* transcript (3D-pellet culture, [Figure 7](#fig7){ref-type="fig"}F) during chondrogenesis suggested that the ectomesenchymal cell-derived chondrocytes matured into hypertrophic chondrocytes.

Such a property of the ectomesenchymal cells might reflect a more general property of hPSC-derived chondrogenic cells. Therefore, we also examined the cartilage particles produced by the hPSC-derived KDR^−^PDGFRα^+^ chondrogenic paraxial mesodermal progeny ([@bib42]). First, we significantly improved the yield of KDR^−^PDGFRα^+^ progeny expressing higher levels of *MEOX1*, *TCF15*, as well as *UNCX* ([Figure S5](#app2){ref-type="sec"}) by replacing BIO with CHIR99021 and inhibiting FGF signaling with PD173074 at a later stage of differentiation. Next, cartilage particles were generated and transplanted subcutaneously. The transplanted particles were mineralized at the periphery, but four of six particles stably maintained internal unmineralized cartilaginous areas even after 12 weeks ([Figure 7](#fig7){ref-type="fig"}A). In some case, the whole cartilaginous particles remained unmineralized ([Figure 7](#fig7){ref-type="fig"}B). These results indicate that the strong tendency of terminal maturation in vivo is not a general property of the hPSC-derived chondrogenic progeny. The neural crest-derived ectomesenchymal cells may innately possess such a property or may have been primed for it during expansion.

Endochondral ossification would replace the transplanted cartilage (consisting of human chondrocytes) with bone tissue made by osteoblasts and osteocytes of murine origin. We therefore addressed the question of whether the donor human chondrocytes completely disappeared from the bony particles generated in 12 weeks. As expected, immunohistochemical analyses revealed that the large hypertrophic chondrocytes showed human-specific signals ([Figure 7](#fig7){ref-type="fig"}G). Interestingly, human cells were also detected in a marrow-like space and around the COL1-positive bone pieces ([Figure 7](#fig7){ref-type="fig"}H), suggesting that the transplanted cartilage particles may contain cells with osteoblastic/osteocytic potential.

Discussion {#sec3}
==========

We have established a novel serum-free culture method for generating and expanding CD271^+^CD73^+^SOX9^+^ chondrogenic ectomesenchymal cells from hPSC-derived, CD271^hi^CD73^−^ neural crest-like progeny. The differentiation pathways from hPSCs to chondrocytes via chondrogenic ectomesenchymal cells postulated from this study are summarized in the [Graphical Abstract](#sec1){ref-type="sec"}. Under optimal conditions, the generation of neural crest-like progeny from hPSCs in CDM was achieved more quickly than previously reported, and the resultant ectomesenchymal cells displayed long-term chondrogenic activity.

Quantitative data on the efficiency of genesis of SOX9-expressing chondroprogenitors from hESCs were first shown by [@bib31]. Under their conditions in which hESC differentiation is directed initially to mesoderm then toward chondrocytes, approximately 8.5 chondroprogenitors of 75%--97% SOX9^+^ are produced per hESC by day 14 of differentiation. In contrast, while only about 0.6 CD271^hi^CD73^−^ neural crest-like progeny were generated per hPSC by day 6 of differentiation in CDM plus SB431542 (data not shown), our method for neural crest-like cell culture in CDM in the presence of FGF2+SB431542 led to 19 to 38 CD271^+^CD73^+^ chondroprogenitors per hPSC by day 14 ([Figure S3](#app2){ref-type="sec"}A). Approximately 76%--85% of these cells continued to express SOX9 protein on days 27--33 (p8--p10), a proportion that increased slightly to about 97% after 3 days of treatment with FGF2+TGFβ3. Further expansion yielded approximately 1 × 10^7^ chondrogenic ectomesenchymal cells per hPSC by day 51 (p16, 24 population doublings). Thus, the method described here allows human chondrogenic cells to expand for an extended period without the loss of purity and chondrogenic activity, resulting in a much larger yield of chondroprogenitor cells (although not homogenous) from hPSCs than previously attained.

The effect of SB431542 on expansion of endothelial progenitors derived from mouse and human ESCs has also been reported ([@bib15; @bib44]). A lack of Nodal/Activin/TGFβ signaling may generally promote proliferation and prevent terminal differentiation of embryonic stem/progenitor cells. In this respect, the ways in which FGF2+SB431542 helps to maintain SOX9 and CD271 while suppressing N-cadherin expression during expansion of the chondrogenic CD271^+^CD73^+^ cells and in which CD271^hi^CD73^−^ neural crest-like cells are directed to give rise to such cells are interesting topics for future study. In this respect, comparative transcriptome analysis has revealed that the CD271^+^CD73^+^ cells accumulated under FGF2+SB431542 conditions possess a similar mRNA profile to primitive neural crest/ectomesenchymal cells, although they lacked *SOX10* expression, which is critical for neural and melanocytic lineage commitment. Thus, suppression of Nodal/Activin/TGFβ signaling does not seem to freeze the developmental stage of the hPSC-derived neural crest during expansion. Such suppression may instead simply support the high proliferative potential of the cells as well as the expression of SOX9 (and *COL2A1*), and thereby maintain chondrogenic activity. *SOX9* expression initiated at the specification and premigratory stages is transient in trunk neural crest but persists in cranial neural crest ([@bib6; @bib7; @bib23]). The chondrogenic CD271^+^CD73^+^ ectomesenchymal cells that maintain *SOX9* transcription and translation (SOX9-GFP^+/lo^) may therefore represent proliferating cranial neural crest, with a slight commitment to non-neural lineages.

Genesis of MSC-like cells from hESCs directly or via neuroectoderm specification has been demonstrated ([@bib5; @bib22]). As shown in [Figure S4](#app2){ref-type="sec"}D, the colonogenic (CFU-F) activity, representing self-renewal activity of MSCs, emerged as early as p2 of the expansion culture under FGF2 alone (i.e., in CD271^−^CD73 cells) or FGF2+SB431542 (i.e., in CD271^+^CD73^+^ cells). However, we were unable to demonstrate significant adipogenic or osteogenic activity in either cell type (data not shown), although the GO analysis predicted osteogenic activity in cells generated under FGF2 (data not shown) and FGF2+SB431542→FGF2 conditions. This discrepancy may be due to some degree of heterogeneity in the cell types generated under these conditions or to the assay method employed, which is widely used for MSCs ([@bib33]), but is less well validated for mesenchymal cells derived from human neural crest. Furthermore, the FGF2+SB431542 conditions applied to the expansion culture of mouse bone marrow MSCs resulted in inhibition of proliferation and promotion of adipocytic differentiation (data not shown). The CD271^+^CD73^+^ ectomesenchymal cells are therefore very likely not to be MSCs, although the possibility that they are derived from an MSC-like precursor has not been excluded.

Thus, hPSC-derived chondrogenic ectomesenchymal cells are amenable to large-scale production in CDM without loss of activity. Although some hESC-derived neural crest stem cells are known to self-renew in culture for an extended period, during which they maintain the capacity to produce multipotential MSC-like activity ([@bib24]), no previous reports have described a method as simple and effective as ours for generating large quantities of (osteo)chondrogenically committed mesenchymal cells under clinically applicable, defined conditions. Therefore, the chondrogenic ectomesenchymal cells produced by the culture technology described are set to become a competitive alternative to adult MSCs, especially for craniofacial regenerative therapy. Moreover, taking advantage of high yields of chondroprogenitor cells, we have successfully modeled neonatal-onset multisystem inflammatory disease by applying our method to patient-derived iPSCs ([@bib46]).

Experimental Procedures {#sec4}
=======================

Cells {#sec4.1}
-----

H9 (WA09), HES3 (ES03), MIXL1-GFP hESCs, and the human fibroblast-derived iPSC line, BJ5, were maintained on feeder cells as described ([@bib42]). The SOX9-GFP hiPSC (CY2-SOX9-2A-ZsGreen-2A-Puro) line from NIH was maintained feeder free in E8 medium.

Neural Crest Cell Differentiation from hPSCs {#sec4.2}
--------------------------------------------

For generating neural crest-like progeny, H9 hESCs and BJ5 hiPSCs were transferred to gelatin-coated dishes and cultured feeder free in the differentiation medium: CDM supplemented with SB431542. The SOX9-GFP hiPSCs were directly induced to differentiate by changing the medium to differentiation medium.

Paraxial Mesoderm Generation from hESCs {#sec4.3}
---------------------------------------

The hPSCs were differentiated as described ([@bib42]) ("2i" condition) or using improvements involving CHIR99021, Noggin, PD173074, and PDGF with or without SB431542 ("3i+P" or "4i+P," [Figure S5](#app2){ref-type="sec"}).

Flow Cytometry {#sec4.4}
--------------

FACS analysis and cell sorting were performed as described ([@bib42]). Intracellular staining for FACS analysis using mouse anti-PAX3 monoclonal antibody was performed according to the manufacturer's recommendations.

Ectomesenchymal Cell Genesis and Expansion {#sec4.5}
------------------------------------------

The differentiated hPSCs before and after sorting for CD271^hi^CD73^−^ were plated onto fibronectin-coated dishes and cultured in CDM supplemented with FGF2 and/or SB431542 (or other small molecules) or in the serum-containing D10 medium.

Immunofluorescence Detection of SOX9 {#sec4.6}
------------------------------------

The CD271^hi^CD73^−^ neural crest-like progeny were cultured in an eight-well chamber slide for 3 days in CDM containing either FGF2+SB431542 or FGF2+TGFβ3 and immunostained with the anti-hSOX9 polyclonal antibody.

Chondrogenesis Assays {#sec4.7}
---------------------

2D-micromass culture and 3D-pellet culture were performed and analyzed as described ([@bib28; @bib40; @bib42]).

Quantification of Sulfated Glycosaminoglycans {#sec4.8}
---------------------------------------------

DNAs and sulfated glycosaminoglycans (sGAGs) from micromasses and cartilage particles were isolated, quantified, and analyzed as described ([@bib47]).

Subcutaneous Transplantation and Immunohistological Analysis {#sec4.9}
------------------------------------------------------------

Cartilaginous particles were transplanted under the dorsal skin of NODScid or NODScid Il2rg^−/−^ (NSG) mice for 8--12 weeks and analyzed as described ([@bib47]). To detect remaining human cells, the fixed particles were first decalcified and then paraffin embedded, sectioned, and stained with the mouse antihuman mitochondria monoclonal antibody.

Gene-Expression Profiling {#sec4.10}
-------------------------

Total RNAs were isolated and reverse transcribed (RT), and real-time PCR was performed using the Taqman Gene Expression Assay. The results were displayed as described ([@bib47]). RNA sequencing was performed on an Illumina HiSeq 1500. Sequenced reads were deposited to Gene Expression Omnibus ([GSE64752](ncbi-geo:GSE64752){#intref0010}) and mapped against the human reference genome (GRCh37). Expression levels were calculated as fragments per kilobase of exon per million mapped fragments (FPKMs) ([Tables S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, [S3](#mmc4){ref-type="supplementary-material"}, and [S4](#mmc5){ref-type="supplementary-material"}).

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures and Figures S1--S6Table S1. Total GO TermsTable S2. Tissue/Cell Development-Related GO TermsTable S3. FSB-Condition-Specific Gene ListTable S4. FSB→F-Condition-Specific Gene ListDocument S2. Article plus Supplemental Information
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![Directed Specification of Neural Crest from hPSCs\
(A) FACS analysis demonstrating the SB431542-dependent development of CD271^hi^PDGFRα^lo^ progeny during 2D differentiation of H9 and MIXL1-GFP hESCs in CDM. SB: 10 μM SB431542.\
(B) Time-dependent changes in the gene expression profile during differentiation of H9 hESCs in the presence of SB (n = 3 technical repeats, mean ± SD).\
(C) Isolation of H9-derived CD271^hi^(PDGFRα^lo^CD73^−^) and CD271^lo^(PDGFRα^−^CD73^−^) progeny by FACS. (Left) Isotype control.\
(D) Real-time RT-PCR analysis with cells from (C) demonstrating enrichment of neural crest-related transcripts in the CD271^hi^CD73^−^ cell fraction. Pre, presort cells (n = 3 technical repeats, mean ± SD).\
(E) Intracellular FACS staining by anti-PAX3 antibody demonstrating presence of PAX3 protein in the H9-derived CD271^hi^CD73^−^ cell fraction. (Upper) Isotype control.\
(F) FACS demonstration of SOX9-GFP expression in the CD271^hi^CD73^−^ progeny in SOX9-GFP hiPSCs differentiated for 6 days.](gr1){#fig1}

![FGF2+SB431542 Generates and Expands *SOX9*-Expressing CD271^+^PDGFRα^+^CD73^+^ Ectomesenchymal Cells from Unsorted Nonmesendodermal Progeny\
(A) Graphical representation of the experimental procedure. SB, SB431542; F, FGF2; FSB, FGF2+SB431542.\
(B) Growth curve of H9 hESC-derived ectomesenchymal cells expanded under F, FSB, and SB conditions (n = 3 independent cultures, mean ± SD).\
(C) FACS analysis demonstrating the effect of FSB on the selective accumulation of CD271^+^CD73^+^ mesenchymal. H9 hESCs and BJ5 hiPSCs were differentiated (Pre) and expanded under the conditions indicated: D10, F, FSB, and FLDN (FGF2+LDN193189). p, passage; isotype control, [Figure S3](#app2){ref-type="sec"}C.\
(D) Micrographs of mesenchymal cells (p4) expanded under F and FSB.\
(E) Real-time RT-PCR analysis demonstrating changes in the neural crest gene expression during expansion under F and FSB (n = 3 technical repeats, mean ± SD).](gr2){#fig2}

![The SOX9-Expressing CD271^+^CD73^+^ Ectomesenchymal Cells Are Chondrogenic and Derived from the CD271^hi^CD73^−^ Neural Crest-like Cell Fraction\
(A) Graphical representation of the experimental procedure.\
(B) FACS analysis of the sorted CD271^hi^CD73^−^ (CD271^hi^) and CD271^lo^CD73^−^ (CD271^lo^) progeny, expanded under F, FSB, FSJN (FGF2+SJN2511), and FA83 (FGF2+A83-01) for three passages.\
(C) Real-time RT-PCR with cells in (B) demonstrating *SOX9* expression specifically maintained in the FSB-expanded CD271^hi^ cells. sort, pre-expanded cells (n = 3 technical repeats, mean ± SD).\
(D) Immunofluorescence detection of SOX9 protein in the FSB-expanded CD271^hi^ cells. Pink, SOX9; blue (nucleus), DAPI; graph, the value of % SOX9^+^ nuclei was the average of scoring from four areas (n = 4 technical repeats, mean ± SD); ++, strong signal; +, weaker signal; isotype control, [Figure S4](#app2){ref-type="sec"}J.\
(E) SOX9-GFP expression in the FSB-expanded CD271^hi^ cells. SOX9-GFP hiPSCs were differentiated, and the CD271^hi^CD73^−^ progeny were isolated and expanded under FSB for five passages as in (A) and then FACS analyzed ([Figure S3](#app2){ref-type="sec"}H). H9 hESC-derived, FSB-expanded cells in (B) were used as the GFP-negative control.\
(F) Chondrogenic activity of the CD271^hi^ or CD271^lo^ progeny maintained under FSB. Cells were grown under FSB and F conditions for five passages and subjected to 2D-micromass cultures, followed by Alcian Blue staining and quantification. ^∗^p \< 0.05 (n = 3 independent cultures, two masses/culture, mean ± SD).](gr3){#fig3}

![Pretreatment with TGFβ Facilitates Cartilage Particle Formation from the FSB-Expanded Ectomesenchymal Cells\
(A and B) Cartilage particle formation from the H9 hESC-derived ectomesenchymal cells maintained under F (A) or FSB (B) by 3D-pellet culture. Toluidine Blue staining (purple) of sections of the cartilage particles, except for (Bvi), which is COL2 immunostained (brown). Some cultures were passaged once or twice (p2) to FT (CDM plus FGF2+TGFβ3) (Aiii, Bi, Bii, Bv, Bvi), or D10 (Aiv, Biii, Biv), prior to pellet culture.\
(C) Capacity of sGAG production in cartilage particles. The ectomesenchymal cells cultured as indicated (→FT, passage to FT) were subjected to pellet culture and total DNA and sGAGs were quantified. Negative control: undifferentiated ESCs. ^∗^p \< 0.05 (n = 3 independent cultures, one pellet/culture mean ± SD).\
(D) Upregulation of N-cadherin surface expression on the FSB-expanded ectomesenchymal cells during FT treatment. The ectomesenchymal cells maintained under F (Fp2) and FSB (FSBp5) were either passaged to FSB (→FSB), FT (→FT, FTp2), or D10 (→D10) or not passaged (Fp2), and then FACS analyzed.\
(E) Effect of FT treatment on SOX9 protein expression. FSB-expanded p7 ectomesenchymal cells followed by FT culture (i.e., p8) were treated and analyzed as in [Figure 3](#fig3){ref-type="fig"}D. Graph, n = 4 technical repeats, mean ± SD. Isotype control, [Figure S4](#app2){ref-type="sec"}J.\
(F) Real-time RT-PCR analysis for investigating the effect of FT treatment on *SOX9* gene expression (n = 3 technical repeats, mean ± SD).](gr4){#fig4}

![The Long-Term Expanded Ectomesenchymal Cells Are Still Dependent on FSB\
(A) SB431542-dependent maintenance of CD271 expression. Ectomesenchymal cells maintained under FSB (p10) were either passaged one to three times to FSB again (p11, p14), or to FGF2 (→F, Fp3) and then FACS analyzed.\
(B) Maintenance of sGAG production capacity. The ectomesenchymal cells maintained under FSB for 11--16 passages followed by FT treatment, and the freshly isolated chondrogenic paraxial mesoderm (PM) ([@bib42]) were subjected to pellet culture. The capacity for sGAG production is displayed as in [Figure 4](#fig4){ref-type="fig"}C. Negative control, hESCs; positive control, bovine articular cartilage (n = 3 technical repeats, mean ± SD).\
(C) "Full-cartilage"-forming capacity remained in the FSB-expanded p13 ectomesenchymal cells derived from CD271^hi^CD73^−^ H9 progeny. Toluidine Blue staining.\
(D) SB431542-dependent maintenance of chondrogenic activity. The p10 ectomesenchymal cells were passaged to either FSB for four passages (FSBp14) or F for two passages (→Fp2) and then subjected to FT treatment and 3D-pellet culture. The capacity for sGAG production is displayed as in (B). ^∗^p \< 0.05 (n ≥ 3 independent cultures, one pellet/culture, mean ± SD).\
(E) Real-time RT-PCR analysis for investigating the effect of FSB on maintaining *SOX9* expression (n = 3 technical repeats, mean ± SD).](gr5){#fig5}

![Comparative Transcriptome Analysis of Ectomesenchymal Cells Using the RNA-seq Technology\
(A) Heat map of the top 250 genes, which are differentially expressed among the three groups. Lanes 1--3: "FSB"; lanes 4, 5, 8: "F"; lanes 6, 7, 9: "FSB→F."\
(B) Principal component analysis of the expression pattern of protein-coding genes among the three groups. Blue, "FSB"; red, "F"; green, "FSB→F."\
(C) Selected list of culture condition-specific genes and common genes. Genes that gave a p \< 0.05 were picked from [Tables S3](#mmc4){ref-type="supplementary-material"} and [S4](#mmc5){ref-type="supplementary-material"} except for few with ^∗^ that gave slightly more variations (0.05 \< p \< 0.1). ND, not determined.\
(D) GO analysis. Selected GO categories from [Table S1](#mmc2){ref-type="supplementary-material"} (upper) and a selected list of development-related GO terms from [Table S2](#mmc3){ref-type="supplementary-material"} (lower).\
(E) RT-PCR confirmation of the relative gene expression levels predicted by the FPKM values (n = 3 independent cultures, mean ± SD).](gr6){#fig6}

![In Vivo Stability of Cartilage Particles Developed with the CD271^+^CD73^+^ Ectomesenchymal Cells\
(A--D) In vivo maturation of cartilage particles developed with the FSB-expanded CD271^+^CD73^+^ ectomesenchymal cells (C and D), generated from H9 hESC-derived CD271^hi^CD73^−^ neural crest-like progeny in comparison with those developed with the freshly isolated KDR^−^PDGFRα^+^ paraxial mesoderm, derived from H9 hESCs under the CHIR99021-based 4i+P conditions (A) and from HES3 hESCs under the BIO-based 2i condition (B) ([@bib42]). Cartilage particles were transplanted into NSG mice (A, C, and D) and NODScid mice (B) subcutaneously for 12 weeks, recovered, fixed, sectioned, and stained with Toluidine Blue (cartilaginous area is in purple) and von Kossa (bony area is in black).\
(E and F) Cartilage gene expression during chondrogenesis cultures. The FSB-expanded p7 cells were subjected to 2D-micromass culture (E) or 3D-pellet culture (F) and then real-time RT-PCR (n = 3 technical repeats, mean ± SD).\
(G and H) Immunostaining with anti-human mitochondria (hMit) antibody. Sections of a bony particle made in (C) and (D) were stained with H&E (G) or stained with hMit antibody (pink, G and H) and anti-type I collagen (COL1) antibody (green, H), followed by counterstaining with DAPI (blue). Negative controls, [Figures S4](#app2){ref-type="sec"}K and S4L.](gr7){#fig7}

[^1]: Present address: Department of Pediatrics, Kyoto University School of Medicine, Kyoto 606-8507, Japan

[^2]: Present address: Houston Methodist Research Institute, Houston, TX 77030, USA

[^3]: Present address: The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA
